Engrail Therapeutics™ announced the acquisition of the biomedical company NeuroCycle Therapeutics, which is committed to the development of the inhibitory neurotransmitter GABA that exists in the human brain -A receptor, this acquisition continues to consolidate Engrail's leading position in the GABA-A category and provides a powerful platform for multiple ongoing clinical trials in 2021.
Dr. Vikram Sudarsan, CEO and President of Engrail Therapeutics, said: "Engrail's flexible trading model and "scientific first" approach allow us to obtain high-quality assets through a lower risk market approach. At the same time, we are fully integrated. Clinical development strategies, regulatory regulations, and comprehensive knowledge of intellectual property rights, so as to find differential assets with proven mechanisms of action. The effect of GABA-A has been fully verified, and the neurotransmitter modulator can be used in a wide range of neurology And play a therapeutic role in psychiatric disorders. We now have a variety of BA-A modulators with powerful properties, and we look forward to rapid development.”
Dr. Vikram Sudarsan continued: "We will continue to work to build a leading and patient-centric neuroscience company, and continue to grow through patent licensing, joint development and acquisition channels. Our goal is to build a diverse neuroscience in the next few years. Scientific treatment methods. The acquisition of NeuroCycle represents an important part of our development path. We expect 2021 to be a busy year because we plan to add more transactions to expand our asset portfolio."
Dr. Jed Hubbs, President of NeuroCycle, said: "NeuroCycle has always focused on the GABA-A space and has extensive experience. The acquisition of Engrail will inherit the work that NeuroCycle has already carried out. We are convinced that this is definitely an ideal company model. At the same time, we look forward to seeing Engrail. Bring new medicines to patients in need."
